GSK's Bepirovirsen Accepted for Expedited Regulatory Review in Japan for Chronic Hepatitis B
Summary
Japan's MHLW has accepted GSK's new drug application for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, for expedited review. This marks the first global regulatory filing for the drug.
Key Events
-
Regulatory Review Accepted in Japan
Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted GSK's New Drug Application (NDA) for bepirovirsen.
-
Expedited Review Status
Bepirovirsen was granted SENKU designation in Japan in August 2024, enabling an expedited regulatory review process.
-
Potential First-in-Class Treatment
The investigational antisense oligonucleotide (ASO) is a potential first-in-class treatment for chronic hepatitis B, a condition affecting nearly one million people in Japan.
-
Supported by Positive Phase III Data
The regulatory submission is backed by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal Phase III B-Well trials.
Analysis
Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted GSK's New Drug Application for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. This marks a significant advancement in the drug's development, following positive Phase III B-Well trials. The SENKU designation, granted in August 2024, ensures an expedited review process, potentially accelerating market access in Japan, a country where nearly one million people live with chronic hepatitis B. This is the first global regulatory filing for bepirovirsen, signaling progress towards commercialization for a drug targeting a major public health challenge.
At the time of this filing, GSK was trading at $59.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $121B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.